Novel 2'-methylidenenucleotide compounds of the formula (I) ##STR1## wherein R is a hydrogen or a halogen, R1 and R2 are the same or different and each is a fatty acid residue or a hydrocarbon residue, and R3 and R4 are the same or different and each is a hydrogen, a halogen or an alkyl; salts thereof; methods for production thereof; and pharmaceutical use thereof. The compounds and salts thereof show an excellent antitumor effect in mammals. More specifically, they show a remarkable activity of inhibiting growth of mouse tumors, cultured human tumor cells, and human tumors transplanted to nude mice, and are useful for the treatment and prevention of recurrence of lung cancer, gastrointestinal cancer, breast cancer, cervical cancer, gynecological cancer, urinological cancer, leukemia, melanoma, lymphogenous metastatic tumor and the like in mammals. They are also useful as antitumor agents since they have an increased bioavailability and low toxicity. In addition, they have the effects of maintaining and enhancing their activities.
|
1. A 2'-methylidenenucleotide compound of the formula (I) ##STR6## wherein R is a hydrogen or a halogen;
R1 and R2 are the same or different and each is a fatty acid residue or a hydrocarbon residue; and R3 and R4 are the same or different and each is a hydrogen, a halogen or an alkyl,
or a salt thereof. 2. The 2'-methylidenenucleotide compound of
3. The 2'-methylidenenucleotide compound of
4. The 2'-methylidenenucleotide compound of
5. The 2'-methylidenenucleotide compound of
6. The 2'-methylidenenucleotide compound of
7. The 2'-methylidenenucleotide compound of
8. A method for producing a 2'-methylidenenucleotide compound of
9. A pharmaceutical composition comprising a 2'-methylidenenucleotide compound of any one of
10. A method for treating a tumor, comprising administering an effective amount of a 2'-methylidenenucleotide compound of any one of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1. Field of the Invention
The present invention relates to novel 2'-methylidene-nucleotide compounds and salts thereof having superior antitumor effect and useful as pharmaceuticals, methods for production thereof, pharmaceutical compositions comprising same as an effective ingredient and methods for treating tumor.
2. Description of Related Art
Nucleoside antitumor agents have been conventionally used for an extensive range of clinical situations against various tumors, but are associated with the following problems. That is, while the activity of said antitumor agents is expressed upon phosphorylation of 5'-position hydroxy, the agents are susceptible to decomposition into inactive substances by phosphorolysis, deamination and so on; the tumor cells come to have resistance to said antitumor agents; and the agents show toxicity to normal cells as well.
Hence, nucleoside antitumor agents free of these problems are desired.
An object of the present invention is to solve the above-mentioned problems and to provide novel 2'-methylidenenucleotide compounds superior to known nucleoside antitumor agents in properties, methods for production thereof and pharmaceutical use thereof.
The present inventors have conducted intensive studies in an effort to accomplish the aforementioned object, and found that novel 2'-methylidenenucleotide compounds of the formula (I) to be shown below and salts thereof have extremely superior properties.
The present invention has been completed based on the above finding, and relates to 2'-methylidenenucleotide compounds of the formula (I) ##STR2## wherein
R is a hydrogen or a halogen;
R1 and R2 are the same or different and each is a fatty acid residue or a hydrocarbon residue; and
R3 and R4 are the same or different and each is a hydrogen, a halogen or an alkyl,
and salts thereof.
Of the compounds of the formula (I), the present invention particularly relates to 2'-methylidenenucleotide compounds wherein R, R3 and R4 are each hydrogen, 2'-methylidene-nucleotide compounds wherein R is fluorine, and R3 and R4 are each hydrogen, 2'-methylidenenucleotide compounds wherein R, R3 and R4 are each hydrogen, and R1 and R2 are the same fatty acid residues, 2'-methylidenenucleotide compounds wherein R is fluorine, R3 and R4 are each hydrogen, and R1 and R2 are the same fatty acid residues, 2'-methylidenenucleotide compounds wherein R, R3 and R4 are each hydrogen, and R1 and R2 are the same fatty acid residues having 12 to 20 carbon atoms, 2'-methylidenenucleotide compounds wherein R is fluorine, R3 and R4 are each hydrogen, and R1 and R2 are the same fatty acid residues having 12 to 20 carbon atoms, and salts thereof.
The present invention also relates to methods for producing 2'-methylidenenucleotide compounds of the above-mentioned formula (I) and salts thereof, comprising reacting a phospholipid of the formula (II) ##STR3## wherein R1 and R2 are as defined above, and R5 is a choline residue, with a nucleoside of the formula (III) ##STR4## wherein R, R3 and R4 are as defined above, in the presence of a phospholipase D.
The present invention also relates to pharmaceutical compositions comprising a 2'-methylidenenucleotide compound of the aforementioned formula (I) or a salt thereof, and a pharmaceutically acceptable carrier. The present invention also relates to methods for treating tumor, comprising administering an effective amount of a 2'-methylidenenucleotide compound of the aforementioned formula (I) or a salt thereof to mammals inclusive of human in need of treating tumor.
(1) Compound
In the present specification, halogen represented by R, R3 and R4 means fluorine, chlorine, bromine and iodine.
The fatty acid residue represented by R1 and R2 means that having 2 to 30, preferably 10-24 and more preferably 12-20 carbon atoms, and may be a saturated fatty acid residue or an unsaturated fatty acid residue. Specific examples of the fatty acid residue include saturated fatty acid residues such as lauroyl, myristoyl, palmitoyl, stearoyl and icosanoyl, and unsaturated fatty acid residues having 1 to 4 unsaturated bonds, such as palmitoleoyl, oleoyl, linoleoyl, linolenoyl and arachidonoyl.
The hydrocarbon residue represented by R1 and R2 means that having 2 to 30, preferably 10-24 and more preferably 12-20 carbon atoms, and may be a saturated hydrocarbon residue or an unsaturated hydrocarbon residue. Specific examples of the hydrocarbon residue include saturated hydrocarbon residues such as lauryl, myristyl, palmityl, stearyl and icosanyl, and unsaturated hydrocarbon residues having 1 to 4 unsaturated bonds, such as palmitoleyl, oleyl, linoleyl, linolenyl and arachidonyl.
The alkyl represented by R3 and R4 means that having 1 to 5 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl and pentyl.
The 2'-methylidenenucleotide compounds of the present invention show superior properties either in the form of salt or hydrate. Examples of such salt include addition salts with inorganic acid (e.g. hydrochloric acid, sulfuric acid, hydrobromic acid and phosphoric acid) or with organic acid (e.g. fumaric acid, tartaric acid, succinic acid, citric acid and methanesulfonic acid); salts with metal (e.g. sodium, potassium and calcium); and ammonium salt. When said salts are used for pharmaceutical compositions, it is desirable that they be pharmaceutically acceptable. Examples of hydrate include that wherein one molecule of a 2'-methylidenenucleotide compound of the present invention or a salt thereof is hydrated with 0.1-3 molecules of water. Isomers are also encompassed in the present invention.
Of such 2'-methylidenenucleotide compounds of the present invention, preferable compounds satisfy at least one of the following conditions 1 to 13:
1 R is hydrogen;
2 R is fluorine;
3 R3 and R4 are the same and are each hydrogen or fluorine;
4 R3 is hydrogen and R4 is fluorine;
5 R3 is fluorine and R4 is hydrogen;
6 R1 and R2 are fatty acid residues;
7 R1 and R2 are the same saturated fatty acid residues;
8 R1 and R2 are the same unsaturated fatty acid residues;
9 R1 and R2 are hydrocarbon residues;
10 R1 and R2 are the same saturated hydrocarbon residues;
11 R1 and R2 are the same unsaturated hydrocarbon residues;
12 the compound is in the form of a salt; and
13 the compound is in the form of a hydrate.
(2) Production method
The 2'-methylidenenucleotide compounds of the present invention can be produced, for example, according to the following reaction scheme. ##STR5## wherein R, R1, R2, R3 and R4 are as defined above and R5 is a choline residue.
That is, the 2'-methylidenenucleotide compound of the present invention can be produced by reacting a phospholipid of the formula (II) with a nucleoside of the formula (III) in a solvent in the presence of a phospholipase D, in coexistence of metallic ion where necessary.
The phospholipid to be used in the method of the present invention includes, for example, phosphatidylcholine having the aforementioned R1 and R2, such as 1,2-diacyl-sn-glycero-3-phosphocholine, 1,2-dialkyl-sn-glycero-3-phosphocholine and 1,2-dialkenyl-sn-glycero-3-phosphocholine. These phosphatidylcholines are commercially available from reagent makers and can be used in the present invention. When R1 and R2 are fatty acid residues, naturally occurring phosphatidylcholine represented by a radyl group, which is a mixture of long chain fatty acids having 12 to 20 carbon atoms, can be also used.
The nucleoside to be used in the present method is represented by the above-mentioned formula (III) and preferable examples thereof include 2'-deoxy-2'-methylidenecytidine (EP-A-0310673, EP-A-0443471), 2'-deoxy-2'-methylidene-5-fluorocytidine (EP-A-0360018), 2'-deoxy-2'-difluoromethylidenecytidine, (E)-2'-deoxy-2'-fluoromethylidenecytidine and (Z)-2'-deoxy-2'-fluoromethylildenecytidine (the last three in EP-A-0372268).
The phospholipase D to be used in the present method is preferably exemplified by phospholipase D-P (Japanese Patent Unexamined Publication No. 152481/1983, commercially available from Asahi Chemical Industry Co., Ltd.) which is derived from Streptomyces sp. AA586; FERM P-6100 belonging to the genus Streptomyces. The amount to be used is 0.01 unit (unit: U) or above, preferably 0.1-100 units, per 1 mg of phosphatidylcholine.
The solvent to be used in the present method is exemplified by two layer solvents comprising organic solvent layer and aqueous solvent layer, such as organic solvents (e.g. ether, benzene and chloroform) and buffer solutions (pH 3-9, preferably pH 4-6).
A metallic ion may be present in a reaction mixture for promoting an enzyme reaction. For forming such metallic ion, a water soluble salt is used, which is generally exemplified by calcium chloride. The reaction temperature is generally 20°-60°C, and the reaction time of 30 minutes to 50 hours is sufficient.
The 2'-methylidenenucleotide compound of the present invention thus obtained can be purified by liquid separation, silica gel chromatography and the like.
The salt and hydrate of the 2'-methylidenenucleotide compound of the present invention can be produced and purified by a method known per se.
(3) Use
The 2'-methylidenenucleotide compounds and salts thereof of the present invention have superior antitumor effect in mammals such as human, mouse, rat, rabbit, dog, cat and the like. They are extremely useful as antitumor agents since they have an increased bioavailability and low toxicity.
That is, the 2'-methylidenenucleotide compounds and salts thereof of the present invention exhibit remarkable effect of inhibiting the growth of mouse tumors such as L1210 leukemia cells, P388 leukemia cells, M5076 sarcoma, B16 mouse melanoma, Lewis lung cancer and Colon 26 colon cancer; cultured human tumor cells (e.g. tumor cells from CEM acute T cell leukemia, U937 human tissue acute leukemia, MOLT4 acute T cell leukemia, K562 chronic myelocytic leukemia, SK-Mel-28 melanoma, T24 bladder cancer, TE2 esophageal gland cancer, SW colon gland cancer, KB epidermic cancer, Lu-65 lung large cell carcinoma, PC13 lung large cell carcinoma, PC14 lung gland cancer and KATOIII stomach cancer); and human tumors transplanted to nude mouse (e.g. tumors of SK-Mel-28 melanoma, LX-1 lung cancer, Lu116 lung cancer, PC10 lung cancer, PC14 lung cancer, MX-1 breast cancer and SC6 stomach cancer). They are useful for the treatment and prevention of recurrence of tumors in mammals inclusive of human, such as lung cancer, gastrointestinal cancers (e.g. esophageal cancer, stomach cancer, large intestin cancer, rectum cancer and colon cancer), breast cancer, cervical cancer, gynecological cancers (e.g. uterine cancer and ovarian cancer), urinological cancers (e.g. kidney cancer, bladder cancer), leukemia, melanoma, lymphogenous metastatic tumor and the like.
The 2'-methylidenenucleotide compounds and salts thereof of the present invention are advantageous in that they are highly liposoluble, so that they reside in the body for a long time while maintaining their activity; are not easily inactivated by deamination, phosphorolysis, reduction and the like; have high affinity for biomembranes; and allow intracellular production of 5'-monophosphoric acid compound of antitumor nucleoside without involvement of kinase. That is, the 2'-methylidenenucleotide compounds and salts thereof of the present invention have the effects of maintaining and enhancing their activities.
When the 2'-methylidenenucleotide compounds and salts thereof of the present invention are used as pharmaceuticals, an effective amount thereof is generally admixed with pharmacologically acceptable carrier, excipient, diluent and the like, and formulated into powder, granule, tablet, sugar-coated tablet, capsule, syrup, suppository, external agent, injection, transfusion and the like, with preferred form being an oral preparation.
While the dose varies depending on the target disease, administration route, dosage form and the like, the 2'-methylidenenucleotide compound or a salt thereof of the present invention is generally administered orally in a dose of 10-400 mg/kg body weight, preferably 50-200 mg/kg body weight per day, or in a dose of 1-10 mg/kg body weight, preferably 1-5 mg/kg body weight per day by injection. The administration frequency can be appropriately selected and is 1 to 4 times a day.
The present invention is described in more detail by way of Examples, to which the present invention is not limited.
2'-Deoxy-2'-methylidenecytidine dihydrate (120 mg, 0.05 mmol) was dissolved in 2.0M sodium acetate buffer (pH 4.5). Phospholipase D-P (PLDP) (3 mg, 522 U) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (404 mg, 0.55 mmol) dissolved in 20 ml of chloroform were added, and the mixture was vigorously stirred at 45°C PLDP (2 mg, 348 U) was added 2 hours later and 4 hours later, and the mixture was stirred for 6 hours in total. The reaction mixture was allowed to cool, and chloroform (20 ml), methanol (20 ml) and water (5 ml) were added to partition the mixture. The lower layer was washed 3 times with methanol-water (1:1, 10 ml), and the solvent was distilled away. The residue was dissolved in a small amount of chloroform-methanol (2:1) and adsorbed on silica gel, which was purified by silica gel column chromatography (φ 2.8 cm×7.5 cm+2.0 cm, eluted with 25% methanol/chloroform) to give a white solid. The solid was dissolved in chloroform-methanol-water (10:5:1) and the mixture was poured on Diaion WK-20 resin column (Na type, φ 2.2 cm×6.0 cm) and eluted with the same solvent, whereby 216 mg (0.24 mmol) of 5'-(1,2-dipalmitoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidenecytidine sodium salt 3/2 hydrate was obtained, yield 48%.
Elemental analysis (C45 H79 N3 O11 PNa . 3/2 H2 O); Calculated C: 58.80, H: 8.99, N: 4.57 Found C: 58.8.2, H: 8.94, N: 4.59
FAB-MS (m/z); 892 (M+)
UV; λmax (MeOH, OH-) 271 nm, λmax (H+) 280 nm
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.82 (d, 1H, 6-H, J6,5 =7.7 Hz), 6.67 (s, 1H, 1'-H), 6.00 (d, 1H, 5-H, J5,6 =7.3 Hz), 5.52 (br.s, 1H, 2'-C═CHa), 5.47 (br.s, 1H, 2'-C═CHb), 5.38-5.21 (m, 1H, glycerol 2-H), 4.79-4.76 (m, 1H, 3'-H), 4.41-3.82 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.32 (t, 2H, COCH2, J=7.7 Hz), 2.31 (t, 2H, COCH2, J=7.7 Hz), 1.60 (m, 4H, COCCH2), 1.26 (m, 48H, palmitoyl CH2), 0.88 (t, 6H, palmitoyl CH3, J=6.6 Hz)
2'-Deoxy-2'-methylidene-5-fluorocytidine (129 mg, 0.50 mmol) was dissolved in 2.0M sodium acetate buffer (pH 4.5). PLDP (3 mg, 522 U) and DPPC (404 mg, 0.55 mmol) dissolved in 20 ml of chloroform were added. The mixture was vigorously stirred at 45°C PLDP (2 mg, 348 U) was added 2 hours later and 4 hours later, and the mixture was stirred for 6 hours in total. The reaction mixture was allowed to cool, and chloroform (20 ml), methanol (20 ml) and water (5 ml) were added to partition the mixture. The lower layer was washed 3 times with methanol-water (1:1, 10 ml), and the solvent was distilled away. The residue was dissolved in a small amount of chloroform-methanol (2:1) and adsorbed on silica gel, which was purified by silica gel column chromatography (φ 2.8 cm×8.0 cm+2.0 cm, eluted with 25% methanol/chloroform) to give a white solid. The solid was dissolved in chloroform-methanol-water (10:5:1) and the mixture was poured on Diaion WK-20 resin column (Na type, φ 2.2 cm×5.5 cm) and eluted with the same solvent, whereby 223 mg (0.25 mmol) of 5'-(1,2-dipalmitoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidene-5-fluoro cytidine sodium salt 1/2 hydrate was obtained, yield 49%.
Elemental analysis (C45 H78 N3 O11 FPNa . 1/2 H2 O); Calculated C: 58.81, H: 8.66, N: 4.57 Found C: 58.72, H: 8.64, N: 4.40
FAB-MS (m/z); 910 (M+)
UV; λmax (MeOH, OH-) 271 nm, λmax (H+) 280 nm
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.73 (d, 1H, 6-H, J6,5F =6.2 Hz), 6.65 (s, 1H, 1'-H), 5.53 (s, 1H, 2'-C═CHa), 5.47 (s, 1H, 2'-C═CHb), 5.24 (m, 1H, glycerol 2-H), 4.73 (m, 1H, 3'-H), 4.21-3.85 (m, 8H, 3',4',5'-H, glycerol 1,3-H), 2.36-2.28 (m, 4H, COCH2), 1.60 (br.s, 4H, COCCH2), 1.43-1.27 (m, 48H, palmitoyl CH2), 0.89 (t, 6H, palmitoyl CH3) In Examples 3 to 8, the following method was used.
2'-Deoxy-2'-methylidenecytidine dihydrate (1.9-3.5 g, 7-12.5 mmol) and calcium chloride dihydrate (1.4 g) were dissolved in purified water (40 ml). The pH of the mixture was adjusted to 4.3-4.5 with 1N hydrochloric acid. PLDP (1-4 mg, 180-720 U) and phosphatidylcholine (0.7-2.9 mmol) dissolved in 80 ml of chloroform were added, and the mixture was vigorously stirred at 35°-40°C for 3-8 hours. The reaction mixture was partitioned between chloroform (53 ml) and methanol (67 ml), and the lower layer was washed by adding methanol (67 ml) and water (40 ml). The solvent was distilled away. The residue was dissolved in a small amount of chloroform-methanol (2:1) and adsorbed on silica gel, which was purified by silica gel column chromatography (elated with chloroform:methanol=3:1) to give a white solid. The solid was dissolved in a chloroform:methanol (2:1) solution (180 ml) and the mixture was partitioned from 0.75N hydrochloric acid (27 ml). Water (27 ml) and methanol (30 ml) were added to the lower layer to partition same (3 times), and methanol (30 ml) was added. The mixture was poured on Diaion WK-20 resin column (Na type) and eluted with chloroform-methanol-water (10:5:1). The solvent was distilled away and acetone was added to the residue to give a powdery object compound.
PAC 5'-(1,2-Distearoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidenecytidine Sodium SaltUsing 2.0 g (2.5 mmol) of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) as phosphatidylcholine, a powdery object compound (1.7 g) was synthesized according to the above-mentioned method, yield 72%.
Elemental analysis (C49 H87 N3 O11 PNa) Calculated C: 62.07, H: 9.25, N: 4.43 Found C: 61.81, H: 9.47, N: 4.53
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.79 (d, 1H, 6-H, J5,6 =7.3 Hz), 6.69 (s, 1H, 1'-H), 5.98 (d, 1H, 5-H, J5,6 =7.3 Hz), 5.51 (s, 1H, --C═CHa), 5.47 (s, 1H, --C═CHb), 5.24-5.22 (m, 1H, glycerol 2-H), 4.79-4.77 (m, 1H, 3'-H), 4.42-3.83 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.35-2.29 (m, 4H, COCH2), 1.61-1.59 (m, 4H, COCCH2), 1.27 (m, 56H, stearoyl CH2), 0.89 (t, 6H, CH3)
PAC 5'-(1,2-Dimyristoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidenecytidine Sodium Salt 3/4 HydrateUsing 2.0 g (2.9 mmol) of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) as phosphatidylcholine, the object compound (1.5 g) was synthesized according to the above-mentioned method, yield 59%.
Elemental analysis (C41 H71 N3 O11 PNa . 3/4 H2 O) Calculated C: 57.97, H: 8.60, N: 4.95 Found C: 57.99, H: 8.83, N: 4.91
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.54 (d, 1H, 6-H, J6,5 =7.6 Hz), 6.63 (s, 1H, 1'-H), 5.86 (d, 1H, 5-H, J5,6 =7.6 Hz), 5.52 (s, 1H, --C═CHa), 5.39 (s, 1H, --C═CHb), 5.23-5.22 (m, 1H, glycerol 2-H), 4.71-4.68 (m, 1H, 3'-H), 4.41-3.82 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.34-2.28 (m, 4H, COCH2), 1.60-1.59 (m, 4H, COCCH2), 1.26 (m, 40H, myristoyl CH2), 0.88 (t, 6H, CH3)
PAC 5'-(1,2-Dioleoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidenecytidine Sodium Salt 1/2 HydrateUsing 1.8 g (2.3 mmol) of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) as phosphatidylcholine, a powdery object compound (1.6 g) was synthesized according to the above-mentioned method, yield 77%.
Elemental analysis (C49 H83 N3 O11 PNa . 1/2 H2 O) Calculated C: 61.74, H: 8.88, N: 4.41 Found C: 61.77, H: 8.93, N: 4.11
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.62 (d, 1H, 6-H, J6,5 =7.8 Hz), 6.66 (s, 1H, 1'-H), 5.99 (d, 1H, 5-H, J5,6 =7.8 Hz), 5.51 (s, 1H, --C═CHa), 5.42 (s, 1H, --C═CHb), 5.39-5.30 (m, 4H, --CH═CH--), 5.24-5.22 (m, 1H, glycerol 2-H), 4.74-4.72 (m, 1H, 3'-H), 4.42-3.81 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.35-2.29 (m, 4H, COCH2), 2.02-1.99 (m, 8H, --CH2 C═CCH2 --), 1.61-1.60 (m, 4H, COCCH2), 1.30-1.27 (m, 40H, oleoyl CH2), 0.89 (t, 6H, CH3)
PAC 5'-(1,2-Dilinoleoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidenecytidine Sodium SaltUsing 1.8 g (2.3 mmol) of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) as phosphatidylcholine, a powdery object compound (1.8 g) was synthesized according to the above-mentioned method, yield 84%.
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.55 (d, 1H, 6-H, J6,5 =7.6 Hz), 6.64 (s, 1H, 1'-H), 5.85 (d, 1H, 5-H, J5,6 =7.6 Hz), 5.52 (s, 1H, --C═CHa), 5.42-5.28 (m, 9H, --C═CHb, --CH═CH--), 5.26-5.20 (m, 1H, glycerol 2-H), 4.71-4.68 (m, 1H, 3'-H), 4.42-3.81 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.77 (t, 4H, C═C--CH2 --C═C), 2.35-2.28 (m, 4H, COCH2), 2.08-2.02 (m, 8H, --CCH2 C═C--), 1.61-1.59 (m, 4H, COCCH2), 1.39-1.22 (m, 28H, linoleoyl CH2), 0.89 (t, 6H, CH3)
PAC 5'-(1,2-O-Dipalmityl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidenecytidine Sodium Salt MonohydrateUsing 0.50 g (0.7 mmol) of 1,2-O-dipalmityl-sn-glycero-3-phosphocholine as phosphatidylcholine, a powdery object compound (0.41 g) was synthesized according to the above-mentioned method, yield 65%.
Elemental analysis (C45 H83 N3 O9 PNa . H2 O) Calculated C: 61.27, H: 9.71, N: 4.76 Found C: 61.23, H: 9.52, N: 4.46
FAB-MS (m/z); 864 (M+)
PAC 5'-(1,2-O-Distearyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidenecytidine Sodium Salt 1/2 HydrateUsing 0.50 g (0.7 mmol) of 1,2-O-distearyl-sn-glycero-3-phosphocholine as phosphatidylcholine, a powdery object compound (0.38 g) was synthesized according to the above-mentioned method, yield 62%.
Elemental analysis (C49 H91 N3 O9 PNa . 1/2 H2 O) Calculated C: 63.34, H: 9.98, N: 4.52 Found C: 63.53, H: 9.72, N: 4.35
FAB-MS (m/z); 920 (M+)
In Examples 9 to 13, the following method was used.
2'-Deoxy-2'-methylidene-5-fluorocytidine (0.65-0.73 g, 2.5-2.8 mmol) and sodium acetate (0.2 g) were dissolved in purified water (10 ml). The pH of the mixture was adjusted to 4.3-4.5 with 1N hydrochloric acid. PLDP (1-3 mg, 180-540 U) and phosphatidylcholine (1.0-1.5 mmol) dissolved in 20 ml of chloroform were added, and the mixture was vigorously stirred at 35°-40°C for 3-20 hours. The reaction mixture was partitioned between chloroform (13 ml) and methanol (16 ml), and the lower layer was washed by adding methanol (16 ml) and water (10 ml). The solvent was distilled away. The residue was dissolved in a small amount of chloroform-methanol (2:1) and adsorbed on silica gel, which was purified by silica gel column chromatography (eluted with chloroform:methanol=3:1) to give a white solid. The solid was dissolved in a chloroform:methanol solution (2:1, 180 ml) and the mixture was partitioned from 0.75N hydrochloric acid (27 ml). Water (27 ml) and methanol (30 ml) were added to the lower layer to partition same (3 times), and methanol (30 ml) was added. The mixture was poured on Diaion WK-20 resin column (Na type) and eluted with chloroform-methanol-water (10:5:1). The solvent was distilled away and acetone was added to the residue to give a powdery object compound.
PAC 5'-(1,2-Distearoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidene-5-fluorocy tidine Sodium Salt 3/2 HydrateUsing 1.0 g (1.2 mmol) of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) as phosphatidylcholine, a powdery object compound (0.31 g) was synthesized according to the above-mentioned method, yield 25%.
Elemental analysis (C49 H86 N3 O11 FPNa . 3/2 H2 O) Calculated C: 59.26, H: 9.03, N: 4.23 Found C: 59.28, H: 9.02, N: 4.06
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.67 (d, 1H, 6-H, J6,5F =5.9 Hz), 6.62 (s, 1H, 1'-H), 5.54 (s, 1H, --C═CHa), 5.45 (s, 1H, --C═CHb), 5.26-5.22 (m, 1H, glycerol 2-H), 4.72-4.69 (m, 1H, 3'-H), 4.42-3.81 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.35-2.28 (m, 4H, COCH2), 1.61-1.59 (m, 4H, COCCH2), 1.26 (m, 56H, stearoyl CH2), 0.88 (t, 6H, CH3)
PAC 5'-(1,2-Dimyristoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidene-5-fluoroc ytidine Sodium Salt MonohydrateUsing 1.0 g (1.5 mmol) of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) as phosphatidylcholine, a powdery object compound (0.33 g) was synthesized according to the above-mentioned method, yield 26%.
Elemental analysis (C41 H70 N3 O11 FPNa . H2 O) Calculated C: 56.47, H: 8.32, N: 4.82 Found C: 56.35, H: 8.18, N: 4.75
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.65 (d, 1H, 6-H, J6,5F =6.3 Hz), 6.62 (s, 1H, 1'-H), 5.55 (s, 1H, --C═CHa), 5.44 (s, 1H, --C═CHb), 5.26-5.22 (m, 1H, glycerol 2-H), 4.71-4.68 (m, 1H, 3'-H), 4.42-3.82 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.35-2.28 (m, 4H, COCH2), 1.61-1.59 (m, 4H, COCCH2), 1.26 (m, 40H, myristoyl CH2), 0.88 (t, 6H, CH3)
PAC 5'-(1,2-Dioleoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidene-5-fluorocyti dine Sodium Salt 1/2 HydrateUsing 0.8 g (1.0 mmol) of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) as phosphatidylcholine, a powdery object compound (0.32 g) was synthesized according to the above-mentioned method, yield 33%.
Elemental analysis (C49 H82 N3 O11 FPNa . 1/2 H2 O) Calculated C: 60.60, H: 8.61, N: 4.33 Found C: 60.46, H: 8.65, N: 4.08
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.63 (d, 1H, 6-H, J6,5F =5.9 Hz), 6.61 (s, 1H, 1'-H), 5.55 (s, 1H, --C═CHa), 5.43 (s, 1H, --C═CHb), 5.39-5.29 (m, 4H, --CH═CH--), 5.25-5.21 (m, 1H, glycerol 2-H), 4.70-4.67 (m, 1H, 3'-H), 4.42-3.81 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.35-2.28 (m, 4H, COCH3), 2.03-2.00 (m, 8H, --CH2 C═CCH2 --), 1.61-1.59 (m, 4H, COCCH2), 1.31-1.27 (m, 40H, oleoyl CH2), 0.88 (t, 6H, CH3)
PAC 5'-(1,2-Dilinoteoyl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidene-5-fluoroc ytidine Sodium Salt DihydrateUsing 0.8 g (1.0 mmol) of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) as phosphatidylcholine, a powdery object compound (0.31 g) was synthesized according to the above-mentioned method, yield 31%.
NMR (CDCl3 --CD3 OD, 3:1) δ; 7.66 (d, 1H, 6-H, J6,5F =5.9 Hz), 6.62 (s, 1H, 1'-H), 5.54 (s, 1H, --C═CHa), 5.45 (s, 1H, --C═CHb), 5.42-5.29 (m, 8H, --CH═CH--), 5.27-5.22 (m, 1H, glycerol 2-H), 4.71-4.68 (m, 1H, 3'-H), 4.42-3.80 (m, 7H, 4',5',5'-H, glycerol 1,3-H), 2.77 (t, 4H, C═C--CH2 --C═C), 2.35-2.28 (m, 4H, COCH2), 2.08-2.02 (m, 8H, --CCH2 C═C--), 1.61-1.60 (m, 4H, COCCH2), 1.39-1.24 (m, 28H, linoleoyl CH2), 0.89 (t, 6H, CH3)
PAC 5'-(1,2-O-Dipalmityl-sn-glycero-3-phospho)-2'-deoxy-2'-methylidene-5-fluoro cytidine Sodium Salt 1/2 HydrateUsing 0.25 g (0.35 mmol) of 1,2-O-dipalmityl-sn-glycero-3-phosphocholine as phosphatidylcholine, a powdery object compound (0.09 g) was synthesized according to the above-mentioned method, yield 29%.
Elemental analysis (C45 H82 N3 O9 FPNa . 1/2 H2 O) Calculated C: 60.65, H: 9.39, N: 4.72 Found C: 60.73, H: 9.30, N: 4.48
FAS-MS (m/z); 882 (M+)
A compound was dissolved in dimethyl sulfoxide and serially diluted with injectable distilled water up to 20-fold diluted final concentration to give test solutions having a concentration of 1.0, 0.5, 0.125 or 0.0625 μg/ml. The test solutions (10 μl) were placed in 96 well microculture plates (Falcon No. 3072), and L1210 leukemia cell suspension (190 μl, 1×105 cells/ml) was added. The mixture was incubated in a CO2 gas incubator at 37°C for 48 hours. As a control, cultures incubated in the same manner but containing 10 μl of injectable distilled water alone were used.
After the incubation, viable cells were counted using an erythrocyte counter according to the trypan blue stain method, and 50% tumor growth inhibition ratio (IC50, μg/ml) was determined.
P388 Leukemia cells (106 cells, obtained from US National Institute of Cancer) were intraperitoneally transplanted to female CDF1 mice (8 weeks of age, 3 per group), and the compound was intraperitoneally administered once a day for 5 consecutive days from the next day of the transplantation. Median survival time (MST) was determined, based on which life prolonging ratio (T/C, %) was calculated from the following equation. ##EQU1##
Human LX-1 lung cancer tumor fragment (2×2×2 mm) was subcutaneously implanted in the back of BALB/C-nu/nu mice. When the volume of the tumor became 100-500 mm3, the mice were divided into several test groups of 4 or 5 mice per group. The test compound was administered once a day for 5 days. The diameter of the tumor was measured and the volume (V) of the tumor was calculated from the following equation ##EQU2## wherein L and W are the major axis and the minor axis of the tumor (mm), respectively. The volume of the tumor in each mouse was calculated and tumor volume ratio Vn /V0 is given. As used herein, Vn is the tumor volume after administration of the test compound for n days and V0 is the initial volume of the tumor before administration of the test compound (Day 0). Vn /V0 (RV) was calculated with respect to each group and efficacy was calculated from the following equation. ##EQU3## In this experiment, the tumor volume was measured at the 7th day from the initial administration, and antitumor effect (tumor growth-inhibitory effect) of respective compounds was studied.
Tablets containing:
| ______________________________________ |
| Compound of the invention |
| 30.0 mg |
| Finely divided cellulose |
| 25.0 mg |
| Lactose 39.5 mg |
| Starch 40.0 mg |
| Talc 5.0 mg |
| Magnesium stearate 0.5 mg |
| ______________________________________ |
When desired, the tablets can be prepared into sugar-coated tablets or film-coated tablets by applying sugar coating or film coating treatment.
Capsules containing the ingredients of:
| ______________________________________ |
| Compound of the invention |
| 30.0 mg |
| Lactose 40.0 mg |
| Starch 15.0 mg |
| Talc 5.0 mg |
| ______________________________________ |
Fine powder containing:
| ______________________________________ |
| Compound of the invention |
| 10% |
| Lactose 80% |
| Starch 10% |
| ______________________________________ |
Granules containing:
| ______________________________________ |
| Compound of the invention |
| 10% |
| Lactose 55% |
| Finely divided cellulose |
| 20% |
| Starch 15% |
| ______________________________________ |
| ______________________________________ |
| Compound of the invention |
| 30.0 mg |
| Glucose 100.0 mg |
| ______________________________________ |
The above ingredients are dissolved in purified water to give an injection (total amount 2 ml).
Suppository containing:
| ______________________________________ |
| Compound of the invention |
| 100 mg |
| Witepsol ® H15 950 mg |
| Witepsol ® E75 950 mg |
| ______________________________________ |
Note that Witepsol is a trademark owned by Witten A-G (Germany).
| ______________________________________ |
| Compound of the invention |
| 2 g |
| Ethyl p-hydroxybenzoate |
| 0.025 g |
| Propyl p-hydroxybenzoate |
| 0.015 g |
| Sodium laurylsulfate |
| 1.5 g |
| Propylene glycol 12.0 g |
| Stearyl alcohol 22.0 g |
| White soft paraffin |
| 25.0 g |
| ______________________________________ |
The above ingredients are dissolved in purified water to give a hydrophilic ointment (total amount 100.0 g).
Ono, Takashi, Sakata, Shinji, Sasaki, Takuma, Matsuda, Akira, Fujii, Akihiro, Miyashita, Takanori, Shutou, Satoshi
| Patent | Priority | Assignee | Title |
| 6475985, | Mar 27 1998 | Regents of the University of Minnesota | Nucleosides with antiviral and anticancer activity |
| 7045543, | Nov 05 2001 | ENZREL INC | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| 8399428, | Dec 09 2004 | Regents of the University of Minnesota | Nucleosides with antiviral and anticancer activity |
| 8765935, | Dec 09 2004 | Regents of the University of Minnesota | Nucleosides with antiviral and anticancer activity |
| 8815830, | Dec 09 2004 | Regents of the University of Minnesota | Nucleosides with antiviral and anticancer activity |
| Patent | Priority | Assignee | Title |
| 3472837, | |||
| 4471113, | Feb 03 1982 | The United States of America as represented by the Department of Energy | Prodrugs based on phospholipid-nucleoside conjugates |
| 4552955, | Jun 29 1981 | Sankyo Chemical Company, Limited | Process for the synthesis of 4',5'-unsaturated nucleosides |
| 4921951, | Sep 27 1986 | Asahi Kasei Kogyo Kabushiki Kaisha | Nucleoside-phospholipid conjugate |
| 4996308, | Mar 25 1988 | AVENTIS INC | Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group |
| 4997924, | Aug 26 1989 | AVENTIS INC | 5'-deoxy-4',5'-unsaturated-5'-substituted adenosines |
| 4997925, | Aug 26 1987 | AVENTIS INC | 5'-deoxy-5',5'-dihalo adenosines and purine analogues |
| 5223263, | Jul 07 1988 | HOSTETLER FAMILY TRUST; HOSTETLER, KARL Y ; CHIMERIX, INC | Liponucleotide-containing liposomes |
| 5378693, | Nov 15 1988 | AVENTISUB INC ; AVENTIS HOLDINGS INC ; Aventisub II Inc | 2'-halomethylidene cytidine, uridine and guanosine compounds and their pharmaceutical compositions |
| 5470837, | Aug 16 1990 | AVENTIS INC | 5'-vinylhalo-aristeromycin/adenosine analogs and immunosuppressants |
| 5484911, | Apr 01 1993 | HEALTH RESEARCH, INC ROSWELL PARK DIV ; UNIV OF GEORGIA RESEARCH FOUNDATION, INC | Nucleoside 5'-diphosphate conjugates of ether lipids |
| 5512671, | Feb 16 1993 | WAKE FOREST UNIVERSITY HEALTH SCIENCES | Ether lipid-nucleoside covalent conjugates |
| 5521162, | Aug 26 1987 | Merrell Pharmaceuticals Inc | Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions |
| EP262876, | |||
| JP2157292, | |||
| JP421694, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jul 14 1995 | SAKATA, SHINJI | Yamasa Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007725 | /0994 | |
| Jul 17 1995 | MIYASHITA, TAKANORI | Yamasa Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007725 | /0994 | |
| Jul 26 1995 | SHUTOU, SATOSHI | Yamasa Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007725 | /0994 | |
| Aug 07 1995 | ONO, TAKASHI | Yamasa Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007725 | /0994 | |
| Aug 10 1995 | FUJII, AKIHIRO | Yamasa Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007725 | /0994 | |
| Sep 15 1995 | Yamasa Corporation | (assignment on the face of the patent) | / | |||
| Sep 15 1995 | Akira, Matsuda | (assignment on the face of the patent) | / | |||
| Sep 15 1995 | Takuma, Sasaki | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Jan 28 1999 | ASPN: Payor Number Assigned. |
| Jul 03 2001 | REM: Maintenance Fee Reminder Mailed. |
| Dec 10 2001 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Jan 15 2002 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Dec 09 2000 | 4 years fee payment window open |
| Jun 09 2001 | 6 months grace period start (w surcharge) |
| Dec 09 2001 | patent expiry (for year 4) |
| Dec 09 2003 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 09 2004 | 8 years fee payment window open |
| Jun 09 2005 | 6 months grace period start (w surcharge) |
| Dec 09 2005 | patent expiry (for year 8) |
| Dec 09 2007 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 09 2008 | 12 years fee payment window open |
| Jun 09 2009 | 6 months grace period start (w surcharge) |
| Dec 09 2009 | patent expiry (for year 12) |
| Dec 09 2011 | 2 years to revive unintentionally abandoned end. (for year 12) |